Invention Grant
- Patent Title: Predicting genetically stable recombinant protein production in early cell line development
-
Application No.: US15525315Application Date: 2015-11-12
-
Publication No.: US10913984B2Publication Date: 2021-02-09
- Inventor: Uro{hacek over (s)} Jamnikar , Kristina Gruden
- Applicant: Lek Pharmaceuticals d.d.
- Applicant Address: SI Ljubljana
- Assignee: Lek Pharmaceuticals d.d.
- Current Assignee: Lek Pharmaceuticals d.d.
- Current Assignee Address: SI Ljubljana
- Agency: Luedeka Neely Group, P.C.
- Priority: EP14192809 20141112
- International Application: PCT/EP2015/076390 WO 20151112
- International Announcement: WO2016/075216 WO 20160519
- Main IPC: C12Q1/6888
- IPC: C12Q1/6888 ; G01N33/50 ; C12N5/073
Abstract:
The present invention relates in general to the field of recombinant protein expression. In particular, the present invention relates to a method for selecting a suitable candidate cell clone for recombinant protein expression and to a host cell for recombinant protein expression, the host cell exhibiting artificially modified gene expression of at least one gene selected from the group consisting of: Hist1h2bc, Egrl, BX842664.2/Hist 1h3c, Dhfr, Fgfr2, AC115880.11, Mmp10, Vsnll (optional), CU459186.17, El 30203 B14Rik, Cspg4, C1qtnf1, Foxp2, and Ptpre.
Public/Granted literature
- US20170314082A1 Predicting Genetically Stable Recombinant Protein Production In Early Cell Line Development Public/Granted day:2017-11-02
Information query
